4 Folgen

MedEdTalks Oncology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on different oncology topics, starting with PTCL. In the first season, we will be talking with Dr. Owen O'Connor from Columbia University in New York City, Dr. Tim Illidge from University of Manchester in the United Kingdom and Dr. Lorenz Trumper from Göttingen University in Germany.

MedEdTalks - Oncology Owen A. O'Connor, MD

    • Medizin

MedEdTalks Oncology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on different oncology topics, starting with PTCL. In the first season, we will be talking with Dr. Owen O'Connor from Columbia University in New York City, Dr. Tim Illidge from University of Manchester in the United Kingdom and Dr. Lorenz Trumper from Göttingen University in Germany.

    Updates in Newly-Diagnosed PTCL

    Updates in Newly-Diagnosed PTCL

    Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in the management of newly diagnosed PTCL.
    To earn CME credit, follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-updates-in-newly-diagnosed-ptcl 
    Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_updates-in-newlydiagnosed-ptcl.pdf 
     

    • 14 Min.
    Antibody-Drug Conjugates in PTCL

    Antibody-Drug Conjugates in PTCL

    Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL.
    To earn CME Credit, please follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-antibody-drug-conjugates-in-ptcl 
    Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_antibodydrug-conjugates-in-ptcl.pdf 

    • 15 Min.
    Options for Relapsed/Refractory PTCL

    Options for Relapsed/Refractory PTCL

    Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss options for managing relapsed/refractory PTCL.
    To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-options-for-relapsed-refractory-ptcl

    • 24 Min.
    Updates in Diagnosis of PTCL and the Role of CD30

    Updates in Diagnosis of PTCL and the Role of CD30

    Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in diagnosis of PTCL and the role of CD30.
    To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-updates-in-diagnosis-of-ptcl-and-the-role-of-cd30

    • 16 Min.

Top‑Podcasts in Medizin